Scarica l'app Stockscreener
17.42
1.75%
0.30
Dopo l'orario di chiusura:
17.50
0.08
+0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Is Viatris Stock Outperforming the S&P 500? - finance.yahoo.com
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - marketscreener.com
Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com
Oppenheimer initiates Viatris stock with outperform rating - Investing.com
Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com UK
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - finance.yahoo.com
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Piper Sandler raises Viatris stock price target on patch growth - Investing.com
Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com
Japan approves a first-of-its-kind treatment for narcolepsy and sleep apnea - Stock Titan
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - finance.yahoo.com
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews
Viatris' China Policy Concerns Overstated, UBS Says - Moomoo
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Healthcare Giant with a 13.99% Upside and Strategic Collaborations - DirectorsTalk Interviews
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris Inc (VTRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan
ETFs Investing in Viatris, Inc. Stocks - TradingView
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Harrow adds TYRVAYA's global rights to dry eye portfolio - Glance by Eyes On Eyecare
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run - Sahm
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView
Viatris Inc. (VTRS) Stock Analysis: Unveiling a 12.6% Potential Upside Amidst Strong Cash Flow - DirectorsTalk Interviews
Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback - simplywall.st
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program - finance.yahoo.com
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval - Yahoo Finance
Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress - Yahoo Finance
3.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):